Union Health Ministry Proposes Simplified Import Rules for Small‑Quantity Drugs and Revised Shelf‑Life Norms (2026)

The Union Health Ministry has moved to simplify the import of small‑quantity drugs needed for analytical and non‑clinical testing. The proposal amends the Drugs Rules, 1945 and introduces an acknowledgement‑based system for such imports. At the same time, a separate draft seeks to change the residual‑shelf‑life requirement from a percentage‑based rule to a fixed 12 months minimum. Key Developments Importers will submit a prior intimation form; an electronic acknowledgement will permit import without a separate licence. The simplified route applies to all drugs for analytical and non‑clinical testing except for certain high‑risk categories such as sex hormones, cytotoxic drugs, beta‑lactam antibiotics, live‑microbe biologics, and narcotic/psychotropic substances. A similar notification system was already introduced in January 2026 for domestic test licences under the New Drugs and Clinical Trials Rules, 2019 . The present amendment extends it to imports. The draft also proposes to replace the existing “more than 60 % residual shelf‑life” rule with a fixed minimum of 12 months at the time of import, except for biological products and radiopharmaceuticals , which will retain the 60 % rule. Important Facts The amendment aims to cut compliance burden for start‑ups and R&D units by removing licence requirements for small‑quantity imports. By guaranteeing a 12‑month residual shelf‑life, the proposal seeks to reduce medicine wastage and improve supply‑chain efficiency. The changes do not affect other quality, safety or efficacy standards under the Drugs and Cosmetics Act, 1940 . UPSC Relevance Understanding these regulatory tweaks is essential for GS III (Health, Pharmaceuticals) and GS II (Polity) questions. The move reflects the government's broader “ease of doing business” agenda, especially for the burgeoning pharma‑R&D sector. Aspirants should note how policy instruments (rules, notifications) are used to balance public‑health safety with industry growth. Way Forward Stakeholders can submit comments on the draft during the public‑consultation period. If adopted, importers will need to set up an online intimation system and align inventory planning with the 12‑month shelf‑life norm. Monitoring will focus on ensuring that exempted high‑risk drugs continue to be tightly regulated.